vTv Therapeutics/VTVT



About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.





Trading on



Biotechnology & Drugs


Paul Sekhri




High point, United States

vTv Therapeutics Metrics

Market cap
P/E ratio
Dividend rate

vTv Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
Q4 23
QoQ growth
Net income
Profit margin
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events


What’s the current market cap for vTv Therapeutics stock?

vTv Therapeutics (VTVT) has a market cap of $76.16M as of April 13, 2024.

What is the P/E ratio for vTv Therapeutics stock?

The price to earnings (P/E) ratio for vTv Therapeutics (VTVT) stock is 0 as of April 13, 2024.

Does vTv Therapeutics stock pay dividends?

No, vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next vTv Therapeutics dividend payment date?

vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders.

What is the beta indicator for vTv Therapeutics?

vTv Therapeutics (VTVT) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the vTv Therapeutics stock price target?

The target price for vTv Therapeutics (VTVT) stock is $, which is 100% below the current price of $24.52. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell vTv Therapeutics stock

Buy or sell vTv Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing